{"transactions":[{"id":700045,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-01T00:00:16.000Z","date":"2026-07-31","kind":"gift","planned":false,"acquired":false,"shares":123840,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":264742,"source":{"system":"sec-edgar","filing":"0001864158-26-000006","document":"form4-07312026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000006/form4-07312026_080701.xml","form_type":"4"}},{"id":711234,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-11T00:00:05.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":697550,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001864158-26-000004","document":"form4-07102026_080702.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000004/form4-07102026_080702.xml","form_type":"4"}},{"id":711233,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-11T00:00:05.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":true,"shares":7000,"price":4.21,"value":29470.0,"ownership":{"direct":true},"balance_after":388582,"source":{"system":"sec-edgar","filing":"0001864158-26-000004","document":"form4-07102026_080702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000004/form4-07102026_080702.xml","form_type":"4"}},{"id":955314,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":338100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":338100,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":338100},"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":955313,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":96600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":381582,"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":955312,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":8072,"price":13.73,"value":110828.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."}],"balance_after":284982,"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":1306832,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-09T01:00:05.000Z","date":"2025-01-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":60.0008,"value":300004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":293054,"source":{"system":"sec-edgar","filing":"0001415889-25-001165","document":"form4-01082025_080101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925001165/form4-01082025_080101.xml","form_type":"4"}},{"id":1315208,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-01-04T01:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":283500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":283500,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":283500},"source":{"system":"sec-edgar","filing":"0001415889-25-000675","document":"form4-01032025_080107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925000675/form4-01032025_080107.xml","form_type":"4"}},{"id":1315207,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-04T01:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026."}],"balance_after":298054,"source":{"system":"sec-edgar","filing":"0001415889-25-000675","document":"form4-01032025_080107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925000675/form4-01032025_080107.xml","form_type":"4"}},{"id":1321031,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-28T01:00:05.000Z","date":"2024-12-24","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":56.1922,"value":1404805.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $56.1922 and the range of prices were between $56.00 and $56.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":217054,"source":{"system":"sec-edgar","filing":"0001415889-24-030211","document":"form4-12272024_081201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924030211/form4-12272024_081201.xml","form_type":"4"}},{"id":1345282,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-04T01:00:05.000Z","date":"2024-12-03","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":67,"value":1005000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."}],"balance_after":242054,"source":{"system":"sec-edgar","filing":"0001415889-24-028203","document":"form4-12032024_081201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924028203/form4-12032024_081201.xml","form_type":"4"}},{"id":1349607,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T01:00:06.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":6719,"price":52.0385,"value":349646.6815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":257054,"source":{"system":"sec-edgar","filing":"0001415889-24-027905","document":"form4-11272024_081102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924027905/form4-11272024_081102.xml","form_type":"4"}},{"id":1349606,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T01:00:06.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":18281,"price":51.4322,"value":940232.0482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":263773,"source":{"system":"sec-edgar","filing":"0001415889-24-027905","document":"form4-11272024_081102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924027905/form4-11272024_081102.xml","form_type":"4"}},{"id":1379457,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-30T23:30:06.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":11103,"price":53.9412,"value":598909.1436,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":282054,"source":{"system":"sec-edgar","filing":"0001415889-24-025792","document":"form4-10302024_071002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924025792/form4-10302024_071002.xml","form_type":"4"}},{"id":1379456,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-30T23:30:06.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":13897,"price":53.2237,"value":739649.7589,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":293157,"source":{"system":"sec-edgar","filing":"0001415889-24-025792","document":"form4-10302024_071002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924025792/form4-10302024_071002.xml","form_type":"4"}},{"id":1398529,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-27T23:30:51.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":795,"price":47.8384,"value":38031.528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":307054,"source":{"system":"sec-edgar","filing":"0001415889-24-024074","document":"form4-09272024_110948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924024074/form4-09272024_110948.xml","form_type":"4"}},{"id":1398528,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-27T23:30:51.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":5248,"price":46.855,"value":245895.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":307849,"source":{"system":"sec-edgar","filing":"0001415889-24-024074","document":"form4-09272024_110948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924024074/form4-09272024_110948.xml","form_type":"4"}},{"id":1398527,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-27T23:30:51.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":18957,"price":46.0893,"value":873714.8601,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":313097,"source":{"system":"sec-edgar","filing":"0001415889-24-024074","document":"form4-09272024_110948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588924024074/form4-09272024_110948.xml","form_type":"4"}},{"id":1693155,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T21:49:50.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":356500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":356500,"derivative":{"exercise_price":11.02,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":356500},"source":{"system":"sec-edgar","filing":"0001209191-24-000431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000120919124000431/doc4.xml","form_type":"4"}},{"id":2063072,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:30:44.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":310000,"derivative":{"exercise_price":14.02,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-23-001867","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000120919123001867/doc4.xml","form_type":"4"}},{"id":2444487,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:21:43.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":354250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":354250,"derivative":{"exercise_price":20.24,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":354250},"source":{"system":"sec-edgar","filing":"0001209191-22-001813","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000120919122001813/doc4.xml","form_type":"4"}}]}